Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: From the bench to the clinic and back again

Regenerative Medicine

Volumn 7, Issue 3, 2012, Pages 409-419

  Patterson, Joseph T ^a   Gilliland, Thomas ^a   Maxfield, Mark W ^b   Church, Spencer ^a   Naito, Yuji ^a   Shinoka, Toshiharu ^a   Breuer, Christopher K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

congenital heart surgery; drug eluting scaffold; tissue engineering; tissue engineered vascular graft; vascular graft

Indexed keywords

ACETYLSALICYLIC ACID; ALGINIC ACID; ALPHA SMOOTH MUSCLE ACTIN; ANGIOPOIETIN 1; BLOOD CLOTTING FACTOR 8; CD146 ANTIGEN; CD31 ANTIGEN; CHITOSAN; DACRON; POLITEF; POLYCAPROLACTONE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYLACTIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VASCULOTROPIN; VON WILLEBRAND FACTOR; WARFARIN;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL GRAFT; BONE MARROW CELL; CELL INFILTRATION; CELL MIGRATION; CONGENITAL HEART DISEASE; EXTRACELLULAR MATRIX; FONTAN PROCEDURE; GRAFT FAILURE; HEART SINGLE VENTRICLE; HUMAN; INFLAMMATORY CELL; MONONUCLEAR CELL; NONHUMAN; PHENOTYPE; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE ENGINEERING; TISSUE REGENERATION;

ANIMALS; BLOOD VESSEL PROSTHESIS; CLINICAL TRIALS AS TOPIC; HEALTH; HEART DEFECTS, CONGENITAL; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84861321536     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.12.12     Document Type: Article

References (49)

1. Connelly M, Webb G, Somerville J et al. Canadian consensus conference on adult congenital heart disease 1996. Can. J. Cardiol. 14(3), 395-452 (1998).
2. Webb CL, Jenkins KJ, Karpawich PP et al. Collaborative care for adults with congenital heart disease. Circulation 105(19), 2318-2323 (2002).
3. Hager A, Kaemmerer H, Eicken A, Fratz S, Hess J. Long-term survival of patients with univentricular heart not treated surgically. J. Thorac. Cardiovasc. Surg. 123(6), 1214-1217 (2002).
4. Samánek M. Children with congenital heart disease: probability of natural survival. Pediatr. Cardiol. 13(3), 152-158 (1992).
5. Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax 26(3), 240-248 (1971).
6. Fontan F. Atrio-pulmonary conduit operations for tricuspid atresia and single ventricle. Nihon Kyobu Geka Gakkai Zasshi 26(3), 276-284 (1978).
7. Ohuchi H, Kagisaki K, Miyazaki A et al. Impact of the evolution of the Fontan operation on early and late mortality: a single-center experience of 405 patients over 3 decades. Ann. Thorac. Surg. 92(4), 1457-1466 (2011).
8. Marcelletti C, Corno A, Giannico S, Marino B. Inferior vena cava-pulmonary artery extracardiac conduit. A new form of right heart bypass. J. Thorac. Cardiovasc. Surg. 100(2), 228-232 (1990).
9. Mayer J, Bridges N, Lock J, Hanley F, Jonas R, Castaneda A. Factors associated with marked reduction in mortality for Fontan operations in patients with single ventricle. J. Thorac. Cardiovasc. Surg. 103(3), 444-451 (1992).
10. Giannico S, Hammad F, Amodeo A et al. Clinical outcome of 193 extracardiac fontan patients: the first 15 years. J. Am. Coll. Cardiol. 47(10), 2065-2073 (2006).
11. Wells W, Malas M, Baker CJ, Quardt SM, Barr ML. Depopulated vena caval homograft: a new venous conduit. J. Thorac. Cardiovasc. Surg. 126(2), 498-503 (2003).
12. Petrossian E, Reddy VM, McElhinney DB et al. Early results of the extracardiac conduit Fontan operation. J. Thorac. Cardiovasc. Surg. 117(4), 688-696 (1999).
13. Alexi-Meskishvili V, Ovroutski S, Ewert P et al. Optimal conduit size for extracardiac Fontan operation. Eur. J. Cardio-Thorac. Surg. 18(6), 690-695 (2000).
14. Pearl J, Laks H, Drinkwater D, Capouya E, George B, Williams R. Modified Fontan procedure in patients less than 4 years of age. Circulation 86(Suppl. 5), II100-II105 (1992).
15. Ovroutski S, Ewert P, Alexi-Meskishvili V et al. Comparison of somatic development and status of conduit after extracardiac Fontan operation in young and older children. Eur. J. Cardiothorac. Surg. 26(6), 1073-1079 (2004).
16. Van Son J, Reddy M, Hanley F. Extracardiac modification of the Fontan operation without use of prosthetic material. J. Cardiothorac. Surg. 110(6), 1766-1768 (1997).
17. Hvass U, Pansard Y, Böhm G, Depoix JP, Enguerrand D, Worms AM. Bicaval pulmonary connection in tricuspid atresia using an extracardiac tube of autologous pediculated pericardium to bridge inferior vena cava. Eur. J. Cardiothorac. Surg. 6(1), 49-51 (1992).
18. Woods RK, Dyamenahalli U, Duncan BW, Rosenthal GL, Lupinetti FM. Comparison of extracardiac Fontan techniques: pedicled pericardial tunnel versus conduitreconstruction. J. Thorac. Cardiovasc. Surg. 125(3), 465-471 (2003).
19. Adachi I, Yagihara T, Kagisaki K et al. Fontan operation with a viable and growing conduit using pedicled autologous pericardial roll: serial changes in conduit geometry. J. Thorac. Cardiovasc. Surg. 130(6), 1517-1522 (2005).
20. Bell E. Tissue engineering in perspective. In:Principles of Tissue Engineering . Lanza RP, Vacanti J (Eds). Elsevier Academic Press, MA, USA, XXXV-XII (2007).
21. Shinoka T, Shum-Tim D, Ma PX et al. Creation of viable pulmonary artery autografts through tissue engineering. J. Thorac. Cardiovasc. Surg. 115(3), 536-546 (1998).
22. Watanabe M, Shin'oka T, Tohyama S et al. Tissue-engineered vascular autograft: inferior vena cava replacement in a dog model. Tissue Eng. 7(4), 429-439 (2001).
23. Shin'oka T, Imai Y, Ikada Y. Transplantation of a tissue-engineered pulmonary artery. N. Engl. J. Med. 344(7), 532-533 (2001).
24. Breuer CK, Shin'oka T, Tanel RE et al. Tissue engineering lamb heart valve leaflets. Biotechnol. Bioeng. 50(5), 562-567 (1996).
25. Noishiki Y, Tomizawa Y, Yamane Y, Matsumoto A. Autocrine angiogenic vascular prosthesis with bone marrow transplantation. Nat. Med. 2(1), 90-93 (1996).
26. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85(3), 221-228 (1999).
27. Kaushal S, Amiel GE, Guleserian KJ et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat. Med. 7(9), 1035-1040 (2001).
28. Matsumura G, Miyagawa-Tomita S, Shin'oka T, Ikada Y, Kurosawa H. First evidence that bone marrow cells contribute to the construction of tissue-engineered vascular autografts in vivo. Circulation 108(14), 1729-1734 (2003).
29. Bitondo JM, Daggett WM, Torchiana DF et al. Endoscopic versus open saphenous vein harvest: a comparison of postoperative wound complications. Ann. Thorac. Surg. 73(2), 523-528 (2002).
30. Shin'oka T, Matsumura G, Hibino N et al. Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. J. Thorac. Cardiovasc. Surg. 129(6), 1330-1338 (2005).
31. Poh M, Boyer M, Solan A et al. Blood vessels engineered from human cells. Lancet 365(9477), 2122-2124 (2005).
32. Naito Y, Imai Y, Shin'oka T et al. Successful clinical application of tissue-engineered graft for extracardiac Fontan operation. J. Thorac. Cardiovasc. Surg. 125(2), 419-420 (2003).
33. Chowdhury UK, Airan B, Kothari SS et al. Specific issues after extracardiac fontan operation: ventricular function, growth potential, arrhythmia, and thromboembolism. Ann. Thorac. Surg. 80(2), 665-672 (2005).
34. Kim SJ, Kim WH, Lim HG, Lee JY. Outcome of 200 patients after an extracardiac Fontan procedure. J. Thorac. Cardiovasc. Surg. 136(1), 108-116 (2008).
35. Hibino N, McGillicuddy E, Matsumura G et al. Late-term results of tissue-engineered vascular grafts in humans. J. Thorac. Cardiovasc. Surg. 139(2), 431-436 (2010).
36. Brennan MP, Dardik A, Hibino N et al. Tissue-engineered vascular grafts demonstrate evidence of growth and development when implanted in a juvenile animal model. Ann. Surg. 248(3), 370-377 (2008).
37. Udelsman B, Hibino N, Villalona GA et al. Development of an operator-independent method for seeding tissue-engineered vascular grafts. Tissue Eng. Part C Methods 17(7), 731-736 (2011).
38. Roh JD, Nelson GN, Brennan MP et al. Small-diameter biodegradable scaffolds for functional vascular tissue engineering in the mouse model. Biomaterials 29(10), 1454-1463 (2008).
39. Wang X, Lin P, Yao Q, Chen C. Development of small-diameter vascular grafts. World J. Surg. 31(4), 682-689 (2007).
40. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin. Immunol. 20(2), 86-100 (2008).
41. Nelson GN, Roh JD, Mirensky TL et al. Initial evaluation of the use of USPIO cell labeling and noninvasive MR monitoring of human tissue-engineered vascular grafts in vivo. FASEB J. 22(11), 3888-3895 (2008).
42. Mirensky TL, Nelson GN, Brennan MP et al. Tissue-engineered arterial grafts: long-term results after implantation in a small animal model. J. Pediatr. Surg. 44(6), 1127-1133 (2009).
43. Salcedo R, Ponce ML, Young HA et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96(1), 34-40 (2000).
44. Mirensky TL, Hibino N, Sawh-Martinez RF et al. Tissue-engineered vascular grafts: does cell seeding matter? J. Pediatr. Surg. 45(6), 1299-1305 (2010).
45. Matsumura G, Hibino N, Ikada Y, Kurosawa H, Shin'oka T. Successful application of tissue engineered vascular autografts: clinical experience. Biomaterials 24(13), 2303-2308 (2003).
46. Roh JD, Sawh-Martinez R, Brennan MP et al. Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc. Natl Acad. Sci. USA 107(10), 4669-4674 (2010).
47. Harrington JK, Chahboune H, Criscione JM et al. Determining the fate of seeded cells in venous tissue-engineered vascular grafts using serial MRI. FASEB J. 25(12), 4150-4161 (2011).
48. Hibino N, Villalona G, Pietris N et al. Tissue-engineered vascular grafts form neovessels that arise from regeneration of the adjacent blood vessel. FASEB J. 25(8), 2731-2739 (2011).
49. Hibino N, Yi T, Duncan DR et al. A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts. FASEB J. 25(12), 4253-4263 (2011).